Skip to main navigation
  • Patient Advocacy
  • Investigator Studies
  • Educational Grants
Coherus Oncology logo
  • Company
    • About Us
    • Leadership
    • Partnering
    • Patient Advocacy
    • Contact
  • Science
    • Oncology Therapeutics
    • Scientific Posters
  • Medicines
    • Product Portfolio
    • Patient Support Services
    • Medical Information Support
  • Pipeline
    • Our Pipeline
    • Toripalimab-tpzi (PD-1)
    • Casdozokitug (IL-27)
    • Tagmokitug (CCR8)
    • CHS-1000 (ILT4)
    • Clinical Trials
  • Careers
    • Our Culture
    • Job Openings
  • Investors & Media
    • Corporate Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
      • IRC Section 6045B Reporting
      • Analyst Coverage
    • SEC Filings
    • Corporate Governance
      • Governance Documents
      • Management Team
      • Board of Directors
    • Shareholder Services
Select Page

Press Releases

Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)
Jan 05, 2026
Pagination
  • First page «
  • Previous page ‹
  • Page 1
  • Current page 2
Coherus Oncology logo white

Follow Us

Company
  • About Us
  • Leadership
  • Partnering
  • Patient Advocacy
  • Contact
Science
  • Oncology Therapeutics
  • Scientific Posters
Medicines
  • Product Portfolio
  • Patient Support Services
  • Medical Information Support
Pipeline
  • Our Pipeline
  • Toripalimab-tpzi (PD-1)
  • Casdozokitug (IL-27)
  • Tagmokitug (CCR8)
  • CHS-1000 (ILT4)
  • Clinical Trials
Careers
  • Our Culture
  • Job Openings
Investors & Media
  • Corporate Overview
  • Press Releases
  • Events & Presentations
  • Stock Information
  • SEC Filings
  • Corporate Governance
  • Shareholder Services
© 2026 Coherus Oncology
  • Privacy Policy
  • Return Goods Policy

Website by 22 Fillmore